Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Opinion - Discussing the market potential of TYMLOS (Abaloparatide) after approval and positive ACTIVExtend results in osteoporosis.

Ticker(s): RDUS, MRK, AMGN, LLY

Who's the expert?

Name: Dr Julia Charles - MD, PhD

Institution: Brigham and Women's Hospital

  • Rheumatologist (Clinician scientist) at BWH who runs a Fracture Liaison Clinic in conjunction with the Department of Orthopedics at BWH Faulkner Hospital.
  • Treats ~100 women currently with osteoporosis.
  • Research interest in osteoclast-osteoblast interactions, inflammatory bone loss and the role of the gut microbiome in modulating host bone turnover. 

Interview Questions
Q1.

Please describe your clinical practice and how many postmenopausal women you treat with osteoporosis at high risk for fracture.

Added By: c_admin
Q2.

Which of your patients are you most likely to have try TYMLOS?

Added By: c_admin
Q3.

How do you view the side effect profile of TYMLOS? Does the black box warning on osteosarcoma concern you?

Added By: c_admin
Q4.

Please explain the mode of action and can you compare the benefit vs other products including
1. Decrease in fracture risk at the femoral neck and lumbar spine
2. Increase in BMD vs competitors 

Added By: c_admin
Q5.

FORTEO and abaloparatide-SC are daily injections, whereas romosozumab is injected once a month. How will this affect the popularity of each drug?  Do these differences suggest romosozumab fits a niche market within osteoporosis?

Added By: c_admin
Q6.

How does the side effect profile of TYMLOS compare to Forteo and Prolia in your opinion?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.